Human herpesviruses and atherosclerosis. Modern point of view

Nikitskaya, E.; Maryukhnich, Elena; Savvinova, Polina; Pinegina, N.; Shpektor, A.; Vasilieva, Elena; Margolis, Leonid

doi:10.15275/kreatkard.2015.02.05

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the question on the effect of chronic HHV-6 infection in ADHF and/or adverse LV remodeling remains controversial. Numerous works were devoted to studying the role of herpes type 6 in pediatrics and neurology [22] due to the vivid clinical picture [23]. This became another reason for studying the HHV-6 prevalence and the clinical, instrumental, and laboratory features in HHV-6-positive patients with ADHF and/or adverse LV remodeling.…”

Section: Discussionmentioning

confidence: 99%

Features of the course of acute decompensated ischemic heart failure and/or ongoing adverse left ventricular remodeling in patients with identified human herpes virus type 6

Kruchinkina

Ogurkova

Гусакова

et al. 2021

SJCEM

View full text Add to dashboard Cite

Objective. To determine serum levels of immunoglobulin M (IgM) and G (IgG) antibodies to human herpes virus type 6 (HHV-6) (anti-HHV-6) and features of clinical and morphological portrait in patients with acute decompensated heart failure (ADHF) of ischemic genesis and/or adverse left ventricular (LV) remodeling.Material and Methods. This open-label, nonrandomized, single-center, prospective trial was registered at clinicaltrials. gov (#NCT02649517) and comprised 25 patients (84% men) with ADHF and LV ejection fraction (EF) ≤ 40%. All patients underwent endomyocardial biopsy (EMB) with immunohistochemistry (IHC) analysis for the presence of HHV-6, compliment C1q, major histocompatibility complex of class II (MHC II), and B-lymphocyte antigen (CD19) as the markers of autoimmune reaction as well as the serum levels of anti-HHV-6 IgM and IgG. Serum levels of IgM and IgG were measured using enzymelinked immunosorbent assay (ELISA) with the calculation of positivity coefficient (PC) according to manufacturer instructions. The test results were interpreted as positive when PC value was greater than 0.8.Results. The endomyocardial biopsy study detected HHV-6 antigen expression in 15 (60%) out of 25 enrolled patients including 10 cases with diagnosed HHV-6-positive myocarditis and five patients with carriage of viruses. According to IHC, the autoimmune HHV-6 myocarditis was confirmed in three cases (30%). The data of ELISA (n = 18) detected anti-HHV-6 IgM in 5 patients (28%) and anti-HHV-6 IgG in 11 cases (61%). The simultaneous presence of both anti-HHV-6 IgM and IgG was detected in two patients (11%). In addition, anti-HHV-6 IgM and IgG were absent in two (11%) cases. Eight patients (44%) with HHV-6-positive myocarditis included three patients (17%) tested positive for serum anti-HHV-6 IgM, three patients (17%) tested positive for serum anti-HHV-6 IgG, and two patients (11%) who had nether anti-HHV-6 IgM nor anti-HHV-6 IgG in blood serum. Among virus carriers, one patient (20%) was tested positive for anti-HHV-6 IgM and four patients (80%) were tested positive for anti-HHV-6 IgG. The patients without HHV-6 antigen expression (n = 5, 28%) included one patient (5.6%) tested positive for anti-HHV-6 IgM and two patients (11%) tested positive for anti-HHV-6 IgG. The entire sample of patients was divided into two groups depending on the serum level of anti-HHV-6 IgM: group 1 comprised patients tested positive for anti-HHV-6 IgM (n = 5); group 2 comprised patients (n = 13) tested negative for anti-HHV-6 IgM. Clinical and instrumental parameters differed only in the duration of CHF history, which was greater in group 1 than in group 2 (11.0 [8.0; 12.0] vs. 22.5 [14.5; 75.5] months, respectively (p = 0.045). The groups did not significantly differ in the studied markers in myocardial tissue according to the results of IHC analysis. No associations were found between the severity of HHV-6 antigen expression and serum levels of anti-HHV-6 IgM and IgG.Conclusion. Patients with ADHF and/or adverse LV remodeling after complete myocardial revascularization had higher percentage of HHV-6 antigen expression whose severity was not associated with the serum levels of anti-HHV-6 IgM and IgG.

show abstract

Section: Discussionmentioning

confidence: 99%

Features of the course of acute decompensated ischemic heart failure and/or ongoing adverse left ventricular remodeling in patients with identified human herpes virus type 6

Kruchinkina

Ogurkova

Гусакова

et al. 2021

SJCEM

View full text Add to dashboard Cite

show abstract

“…These include the following viruses: Herpesviridae family viruses, enteroviruses, hepatitis viruses, influenza viruses, human immunodeficiency virus, and human papillomavirus. Bacterial infections also play a role, but this review focuses on the role of viruses in the development of atherosclerosis [33][34][35][36][37][38][39][40][41][42].…”

Section: Latent Viral Infections and Atherosclerosismentioning

confidence: 99%

“…The mechanisms of atherogenic HSV effects are very diverse [39] and implicated in the modulation of all elements of atherogenesis including vascular endothelium, smooth muscle cells, and lipoproteins. Endothelial dysfunction during HSV infection occurs in three ways.…”

Section: Herpes Simplex Virus (Hsv) Type 1 Andmentioning

confidence: 99%

Atherosclerosis. Macrophages. Viral infections

Рябов

Алексеева

Gombozhapova

et al. 2021

SMJ

View full text Add to dashboard Cite

The emergence of new COVID-19 infection aggravated the existing issues and gave rise to new challenges associated with the impact of viruses on the atherosclerotic process and development of cardiovascular complications. Atherosclerosis is a multifactorial disease and its progression is largely determined by dyslipidemia and chronic low-grade systemic vascular inflammation. There are a number of viruses known to be involved in maintaining the inflammatory state through the prolonged viral persistence and replication in the macrophages whose plasticity changes due to the infection. The viruses can trigger the pro-atherogenic cytokine response through the diverse macrophage-dependent mechanisms. There is lack of data regarding impact of viral infections on the monocyte/macrophage plasticity and possible control of inflammation in atherogenesis. It is still unclear whether the relationships between the viral diseases and atherosclerosis are causal or merely associative. In this review, we summarize and critically analyze the current state of knowledge regarding the virus-related mechanisms promoting atherosclerosis.

show abstract

“…ОКС при COVID-19. Тромбоз коронарных артерий при COVID-19 может развиваться по двум основным механизмам: во-первых, как проявление коагулопатии, характерной для данного заболевания [17,19,25,26]; во-вторых, вследствие дестабилизации коронарного атеросклероза в ответ на вирусную инфекцию и системное воспаление [27][28][29][30]. По имеющимся данным, ОКС имеет определенный вес в структуре смертности среди госпитализированных пациентов с COVID-19.…”

Section: ïîðàAeåíèå ñåðäå÷íî-ñîñóäèñòîé ñèñòåìû ïðè Covid-19unclassified

Novel coronavirus infection COVID-19: extrapulmonary manifestations

Маев

Shpektor

Vasilyeva

et al. 2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The novel coronavirus infection COVID-19 in most cases manifests with respiratory symptoms and fever, however, some patients may have cardiovascular and gastroenterological manifestations. A feature of the clinical syndrome of COVID-19 is the development of pronounced immunopathological reactions and disorders of hemostasis, leading to the development of a wide range of cardiovascular complications. The course of COVID-19 may be complicated by the development of acute myocardial infarction, venous and arterial thrombosis and thromboembolism in various vascular pools, the development of acute myocardial damage and myocarditis. Among the gastroenterological manifestations, diarrhea, nausea or vomiting, as well as abdominal pain, are most often detected. These symptoms may precede the appearance of respiratory signs of the disease, and in some cases come to the fore in the clinical picture of the disease. In addition, in some patients there are laboratory signs of liver injury (increased serum transaminases). The exact pathogenesis of the above disorders continues to be studied.

show abstract

Human herpesviruses and atherosclerosis. Modern point of view

Cited by 7 publications

References 0 publications

Features of the course of acute decompensated ischemic heart failure and/or ongoing adverse left ventricular remodeling in patients with identified human herpes virus type 6

Features of the course of acute decompensated ischemic heart failure and/or ongoing adverse left ventricular remodeling in patients with identified human herpes virus type 6

Atherosclerosis. Macrophages. Viral infections

Novel coronavirus infection COVID-19: extrapulmonary manifestations

Contact Info

Product

Resources

About